EcoR1 Capital’s Cartesian Therapeutics RNAC Stock Holding History

EcoR1 Capital’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,667	Closed	-$278K	–	63
2023 Q1	$278K	Sell	6,667 -110,000	-94%	-$5.17M	0.01%	54
2022 Q4	$3.96M	Hold	116,667	–	–	0.12%	49
2022 Q3	$5.74M	Hold	116,667	–	–	0.17%	45
2022 Q2	$4.58M	Buy	+116,667	New	+$3.46M	0.16%	49
2020 Q2	–	Sell	-153,257	Closed	-$11.1M	–	64
2020 Q1	$11.1M	Hold	153,257	–	–	1.16%	25
2019 Q4	$10.9M	Buy	+153,257	New	+$7.39M	0.99%	24

Other funds holding RNAC

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital's RNAC Position: Q2 2023 in Review

EcoR1 Capital sold out of Cartesian Therapeutics (RNAC) in Q2 2023, closing a stake of 6,667 shares — an estimated $278K sold.

EcoR1 Capital first reported a position in RNAC in Q4 2019 and held it in 6 quarters. The position peaked at $11.1M in Q1 2020. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2023.

EcoR1 Capital reported no remaining Cartesian Therapeutics position as of Q2 2023 after selling out during the quarter.
EcoR1 Capital sold 6,667 Cartesian Therapeutics shares in Q2 2023, an estimated $278K.
EcoR1 Capital first reported a position in Cartesian Therapeutics in Q4 2019 and held it in 6 quarters.
EcoR1 Capital's Cartesian Therapeutics position peaked at $11.1M in Q1 2020.
92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2023.

Based on EcoR1 Capital's 13F filing for Q2 2023, filed 14 Aug 2023.